Norway Anti-vascular Endothelial Growth Factor Therapeutics Market Size & Outlook
Norway anti-vascular endothelial growth factor therapeutics market, 2018-2030 (US$M)
Related Markets
Norway anti-vascular endothelial growth factor therapeutics market highlights
- The Norway anti-vascular endothelial growth factor therapeutics market generated a revenue of USD 123.9 million in 2024 and is expected to reach USD 96.3 million by 2030.
- The Norway market is expected to grow at a CAGR of -4.4% from 2025 to 2030.
- In terms of segment, eylea was the largest revenue generating product in 2024.
- Vabysmo is the most lucrative product segment registering the fastest growth during the forecast period.
Anti-vascular endothelial growth factor therapeutics market data book summary
| Market revenue in 2024 | USD 123.9 million |
| Market revenue in 2030 | USD 96.3 million |
| Growth rate | -4.4% (CAGR from 2025 to 2030) |
| Largest segment | Eylea |
| Fastest growing segment | Vabysmo |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
| Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, Norway accounted for 0.9% of the global anti-vascular endothelial growth factor therapeutics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany anti-vascular endothelial growth factor therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Sweden is the fastest growing regional market in Europe and is projected to reach USD 126.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-Vascular Endothelial Growth Factor Therapeutics Market Scope
Anti-Vascular Endothelial Growth Factor Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway anti-vascular endothelial growth factor therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.9% in 2024. Horizon Databook has segmented the Norway anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
The Anti-Vascular Endothelial Growth Factor (Anti-VEGF) therapeutics market is experiencing stable growth in Norway, fueled by a combination of economic and demographic factors. Norway's stable GDP is indicative of a healthy economy, allowing for increased investment in healthcare. This economic stability supports the expansion of treatment options, particularly for eye diseases that necessitate AntiVEGF therapies.
A rising prevalence of eye-related conditions such as macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration is driving demand for these therapies. As the population ages, the incidence of these diseases is expected to rise, prompting a greater need for effective treatment options.
Moreover, healthcare providers in Norway are increasingly adopting advanced therapeutic approaches that utilize Anti-VEGF treatments. This trend not only addresses the growing patient needs but also aligns with the country’s commitment to improving healthcare outcomes.
Reasons to subscribe to Norway anti-vascular endothelial growth factor therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway anti-vascular endothelial growth factor therapeutics market databook
-
Our clientele includes a mix of anti-vascular endothelial growth factor therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Norway anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway anti-vascular endothelial growth factor therapeutics market size, by product, 2018-2030 (US$M)
Norway Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
